← Back to Clinical Trials
Recruiting Phase 3 NCT07241390
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Trial Parameters
Condition Atherosclerosis Cardiovascular Disease
Sponsor Eli Lilly and Company
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 7,140
Sex ALL
Min Age 50 Years
Max Age N/A
Start Date 2025-12-01
Completion 2031-08
All Conditions
Interventions
OrforglipronPlacebo
Brief Summary
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Eligibility Criteria
Inclusion Criteria: * Have established ASCVD and/or CKD Exclusion Criteria: * Have type 1 diabetes * Have had a major heart condition within 60 days prior to screening * Have New York Heart Association Functional Classification Class IV heart failure